To compare effectiveness of Lorazepam and Risperidone in the treatment of Cannabis Induced Psychotic Disorder
Not Applicable
Completed
- Conditions
- Health Condition 1: F129- Cannabis use, unspecified
- Registration Number
- CTRI/2021/05/033552
- Lead Sponsor
- Government medical college and hospital Chandigarh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Patients fulfilling the diagnostic criteria for cannabis induced psychotic disorder as
per DSM-5.
18-65 years old Male patients.
Patients willing for admission in ward for treatment.
Patients who test positive for cannabinoids on urine screening.
Patients with a reliable informant.
Patients willing to give consent.
Exclusion Criteria
Patients with comorbid dependence on other substances except caffeine and nicotine.
Patients having current comorbid major mental illness.
Patients with a history of medical/physical illness where the use of Lorazepam/
Risperidone is contraindicated. For e.g. chronic liver disease, chronic kidney disease,
chronic lung disease, head injury etc.
History of hypersensitivity to Lorazepam/ Risperidone.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in the severity of psychopathology as assessed by the administration of various psychiatric rating scales like positive and negative syndrome scale (PANSS) and Young mania rating scale (YMRS) on a daily basis till 10 days after the initiation of treatment.Timepoint: positive and negative syndrome scale (PANSS) and Young mania rating scale (YMRS) shall be administered at baseline and, thereafter, daily for a period of 10 days.
- Secondary Outcome Measures
Name Time Method to assess the severity of dependence, evolution of withdrawal symptoms and craving using the severity of dependence scale (SDS), cannabis withdrawal scale (CWS) and marijuana craving questionnaire (MCQ) respectively.Timepoint: severity of dependence scale (SDS) shall be administered at baseline only. cannabis withdrawal scale (CWS) and marijuana craving questionnaire (MCQ) shall be applied at baseline and, thereafter, daily for a period of 10 days.